Further, the expression of PD-L1 on tumor cells was significantly enhanced in the palbociclib group (Fig. 7f), indicating that CDK4/6 inhibitors re-sensitize tumors to anti-PD-1 treatment. Here, CDK4 is linked to neoplasm.